Lenalidomide maintenance therapy doubled the rate of progression-free survival, compared with placebo for multiple myeloma patients who had completed autologous stem cell transplantation and a lenalidomide consolidation phase in a trial conducted by a French-speaking myeloma group.The 3-year progression-free survival rate was 68% among 307 patients who received lenalidomide (Revlimid) maintenance until relapse, compared with 34% for 307 patients who received placebo. The difference translates into...